J B Chemicals & Pharmaceuticals Financial Statements
J B Chemicals & Pharmaceuticals Annually Results
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | 15.10 | 26 | 4.81 | 11.10 |
| Op profit growth | 48.40 | 73.30 | (6.30) | 12.80 |
| EBIT growth | 66.90 | 83.30 | (16) | 5.58 |
| Net profit growth | 64.70 | 96.60 | (25) | 13.20 |
| Profitability ratios (%) | ||||
| OPM | 27.40 | 21.30 | 15.50 | 17.30 |
| EBIT margin | 29.60 | 20.40 | 14 | 17.50 |
| Net profit margin | 21.90 | 15.30 | 9.82 | 13.70 |
| RoCE | 35 | 23.50 | 13.10 | 16.10 |
| RoNW | 6.90 | 4.73 | 2.47 | 3.61 |
| RoA | 6.49 | 4.42 | 2.29 | 3.16 |
| Per share ratios () | ||||
| EPS | 58 | 35.30 | 16.60 | 21.70 |
| Dividend per share | 16.50 | 11 | 2 | 1 |
| Cash EPS | 49.10 | 26.60 | 9.74 | 16.10 |
| Book value per share | 234 | 186 | 172 | 161 |
| Valuation ratios | ||||
| P/E | 21.60 | 14.40 | 18.60 | 16 |
| P/CEPS | 25.50 | 19.10 | 31.80 | 21.50 |
| P/B | 5.35 | 2.74 | 1.79 | 2.16 |
| EV/EBIDTA | 14.40 | 9.17 | 10.20 | 10.50 |
| Payout (%) | ||||
| Dividend payout | -- | -- | 12.10 | 4.61 |
| Tax payout | (25) | (21) | (28) | (20) |
| Liquidity ratios | ||||
| Debtor days | 65.60 | 66.40 | 73.40 | 73.10 |
| Inventory days | 55.60 | 50.20 | 53.60 | 52.70 |
| Creditor days | (46) | (38) | (35) | (37) |
| Leverage ratios | ||||
| Interest coverage | (83) | (119) | (57) | (44) |
| Net debt / equity | -- | -- | -- | 0.03 |
| Net debt / op. profit | -- | -- | -- | 0.15 |
| Cost breakup () | ||||
| Material costs | (34) | (36) | (38) | (39) |
| Employee costs | (17) | (18) | (18) | (16) |
| Other costs | (22) | (25) | (29) | (27) |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Revenue | 2,043 | 1,775 | 1,409 | 1,344 |
| yoy growth (%) | 15.10 | 26 | 4.81 | 11.10 |
| Raw materials | (701) | (631) | (538) | (528) |
| As % of sales | 34.30 | 35.50 | 38.20 | 39.30 |
| Employee costs | (341) | (323) | (251) | (217) |
| As % of sales | 16.70 | 18.20 | 17.80 | 16.20 |
| Other costs | (440) | (443) | (402) | (367) |
| As % of sales | 21.50 | 25 | 28.50 | 27.30 |
| Operating profit | 560 | 378 | 218 | 232 |
| OPM | 27.40 | 21.30 | 15.50 | 17.30 |
| Depreciation | (69) | (66) | (57) | (47) |
| Interest expense | (7.20) | (3) | (3.50) | (5.40) |
| Other income | 112 | 50.70 | 36.60 | 50.20 |
| Profit before tax | 597 | 359 | 194 | 230 |
| Taxes | (148) | (77) | (55) | (46) |
| Tax rate | (25) | (21) | (28) | (20) |
| Minorities and other | (0.60) | (0.30) | (0.40) | (0.30) |
| Adj. profit | 448 | 282 | 138 | 184 |
| Exceptional items | -- | (10) | -- | -- |
| Net profit | 448 | 272 | 138 | 184 |
| yoy growth (%) | 64.70 | 96.60 | (25) | 13.20 |
| NPM | 21.90 | 15.30 | 9.82 | 13.70 |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
| Profit before tax | 597 | 359 | 194 | 230 |
| Depreciation | (69) | (66) | (57) | (47) |
| Tax paid | (148) | (77) | (55) | (46) |
| Working capital | 50.30 | 18.10 | 65.20 | 37.80 |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | 430 | 234 | 147 | 175 |
| Capital expenditure | 762 | 721 | 516 | 498 |
| Free cash flow | 1,192 | 955 | 663 | 673 |
| Equity raised | 2,020 | 2,100 | 2,306 | 2,197 |
| Investments | 593 | 101 | 36.10 | (89) |
| Debt financing/disposal | (53) | 47.40 | 12.30 | 24.50 |
| Dividends paid | -- | -- | 16.70 | 8.48 |
| Other items | -- | -- | -- | -- |
| Net in cash | 3,751 | 3,203 | 3,035 | 2,814 |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
| Equity capital | 15.50 | 15.50 | 16.10 | 16.70 |
| Preference capital | -- | -- | -- | -- |
| Reserves | 1,794 | 1,420 | 1,464 | 1,425 |
| Net worth | 1,810 | 1,435 | 1,480 | 1,442 |
| Minority interest | ||||
| Debt | 32.60 | 29.50 | 25.80 | 29.30 |
| Deferred tax liabilities (net) | 72.10 | 64.10 | 77.20 | 69.30 |
| Total liabilities | 1,918 | 1,532 | 1,586 | 1,543 |
| Fixed assets | 659 | 667 | 636 | 657 |
| Intangible assets | ||||
| Investments | 678 | 403 | 457 | 434 |
| Deferred tax asset (net) | 22.30 | 16 | 20.30 | 36.90 |
| Net working capital | 528 | 414 | 436 | 385 |
| Inventories | 347 | 275 | 244 | 214 |
| Inventory Days | 62.10 | 56.50 | -- | 55.40 |
| Sundry debtors | 389 | 345 | 308 | 301 |
| Debtor days | 69.50 | 71 | -- | 77.90 |
| Other current assets | 127 | 92.20 | 111 | 130 |
| Sundry creditors | (194) | (176) | (119) | (114) |
| Creditor days | 34.70 | 36.20 | -- | 29.60 |
| Other current liabilities | (141) | (123) | (107) | (145) |
| Cash | 30.90 | 31 | 36.80 | 29.90 |
| Total assets | 1,918 | 1,532 | 1,586 | 1,543 |
- Switch to
-
ConsolidatedStandalone
| Particulars ( Rupees In Crores.) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|---|
| Gross Sales | 2,043 | 1,775 | 1,643 | 1,413 | 1,368 |
| Excise Duty | -- | -- | -- | -- | -- |
| Net Sales | 2,043 | 1,775 | 1,643 | 1,413 | 1,368 |
| Other Operating Income | -- | -- | -- | -- | -- |
| Other Income | 112 | 50.70 | 41.40 | 37.10 | 50.20 |
| Total Income | 2,155 | 1,825 | 1,685 | 1,450 | 1,418 |
| Total Expenditure ** | 1,482 | 1,407 | 1,337 | 1,196 | 1,136 |
| PBIDT | 673 | 418 | 347 | 254 | 283 |
| Interest | 7.24 | 3.03 | 4.65 | 3.49 | 5.37 |
| PBDT | 666 | 415 | 343 | 251 | 277 |
| Depreciation | 68.70 | 66.30 | 55.60 | 57 | 47.20 |
| Minority Interest Before NP | -- | -- | -- | -- | -- |
| Tax | 142 | 84.40 | 93 | 55.20 | 45.60 |
| Deferred Tax | 6.16 | (7.90) | -- | -- | -- |
| Reported Profit After Tax | 449 | 272 | 194 | 139 | 184 |
| Minority Interest After NP | 0.56 | 0.35 | 0.50 | 0.38 | 0.34 |
| Net Profit after Minority Interest | 448 | 272 | 193 | 138 | 184 |
| Extra-ordinary Items | -- | (7.60) | -- | -- | -- |
| Adjusted Profit After Extra-ordinary item | 448 | 280 | 193 | 138 | 184 |
| EPS (Unit Curr.) | 58 | 34.20 | 23.50 | 16.50 | 21.70 |
| Book Value (Unit Curr.) | -- | -- | -- | -- | -- |
| Dividend (%) | 825 | 550 | 250 | 100 | 50 |
| Equity | 15.50 | 15.50 | 16.10 | 16.70 | 17 |
| Public Shareholding (Number) | -- | -- | -- | -- | -- |
| Public Shareholding (%) | -- | -- | -- | -- | -- |
| Pledged/Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Pledged/Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| Non Encumbered - No. of Shares | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Promoters Holding | -- | -- | -- | -- | -- |
| Non Encumbered - % in Total Equity | -- | -- | -- | -- | -- |
| PBIDTM(%) | 32.90 | 23.60 | 21.10 | 18 | 20.60 |
| PBDTM(%) | 32.60 | 23.40 | 20.90 | 17.80 | 20.30 |
| PATM(%) | 22 | 15.30 | 11.80 | 9.82 | 13.50 |
QuickLinks for J B Chemicals & Pharmaceuticals Ltd.
